OverviewSuggest Edit

Repligen Corporation is a company that specializes in the development, production, and commercialization of products used for biological drugs manufacturing. It offers hollow fiber filters, flat sheet cassettes, ligands and resins, TFDF (tangential flow depth filtration) systems, etc. The company focuses on a range of applications, including protein therapeutics, gene therapy, macromolecules, vaccines, and antibody-drug conjugates. 

TypePublic
Founded1981
HQWaltham, MA, US
Websiterepligen.com
Employee Ratings2.5

Latest Updates

Employees (est.) (Dec 2019)761(+39%)
Revenue (FY, 2019)$270.2 M(+40%)
Share Price (Jan 2021)$216.7 (-2%)
Cybersecurity ratingBMore

Key People/Management at Repligen

Tony J. Hunt

Tony J. Hunt

President, Chief Executive Officer
Jon K. Snodgres

Jon K. Snodgres

Chief Financial Officer
Ralf Kuriyel

Ralf Kuriyel

Senior Vice President, Research and Development
Gautam Choudhary

Gautam Choudhary

Vice President, Systems and Automation
Steve Curran

Steve Curran

Vice President, Global Operations
Christine Gebski

Christine Gebski

Senior Vice President, Filtration and Chromatography
Show more

Repligen Office Locations

Repligen has offices in Waltham, Bridgewater Township, Clifton Park, Compton and in 10 other locations
Waltham, MA, US (HQ)
41 Seyon St #100
Bridgewater Township, NJ, US
685 Route 202 / 206
Clifton Park, NY, US
1 Fairchild Sq, Ste 111
Compton, CA, US
18617 S Broadwick St
Irving, TX, US
3400 Royalty Row
Marlborough, MA, US
111 Locke Dr, Marlborough
Show all (14)

Repligen Financials and Metrics

Repligen Revenue

Embed Graph
View revenue for all periods
Repligen's revenue was reported to be $270.25 m in FY, 2019 which is a 39.3% increase from the previous period.
USD

Revenue (Q3, 2020)

94.1m

Gross profit (Q3, 2020)

54.4m

Gross profit margin (Q3, 2020), %

57.9%

Net income (Q3, 2020)

14.6m

EBIT (Q3, 2020)

21.0m

Market capitalization (20-Jan-2021)

11.9b

Closing stock price (20-Jan-2021)

216.7

Cash (30-Sept-2020)

553.3m

EV

11.6b
Repligen's current market capitalization is $11.9 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

141.2m194.0m270.2m

Revenue growth, %

37%39%

Cost of goods sold

67.1m86.5m119.1m

Gross profit

74.2m107.5m151.1m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

44.8m47.7m49.5m60.6m70.7m69.4m76.1m87.5m94.1m

Cost of goods sold

19.7m21.1m22.2m26.8m30.7m31.4m32.0m36.9m39.6m

Gross profit

25.2m26.6m27.3m33.8m40.0m38.0m44.1m50.6m54.4m

Gross profit Margin, %

56%56%55%56%57%55%58%58%58%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

173.8m193.8m528.4m

Accounts Receivable

27.6m33.0m43.1m

Prepaid Expenses

2.3m3.9m5.9m

Inventories

39.0m42.3m54.8m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

173.9m175.6m190.3m196.1m208.9m513.5m529.5m560.4m553.3m

Accounts Receivable

29.4m31.7m30.8m39.3m43.0m42.0m44.7m48.8m

Prepaid Expenses

4.9m4.6m3.8m3.7m3.9m4.9m5.8m7.6m9.0m

Inventories

40.1m40.9m42.3m44.9m51.3m51.6m61.8m69.9m78.5m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

28.4m16.6m21.4m

Depreciation and Amortization

10.5m15.8m20.9m

Inventories

605.0k(4.0m)(9.3m)

Accounts Payable

807.0k2.3m662.0k
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

3.4m6.2m11.0m8.1m16.1m17.8m9.8m25.7m40.2m

Depreciation and Amortization

4.0m7.9m11.8m4.2m9.1m14.8m6.4m12.9m19.6m

Inventories

(1.2m)(3.1m)(4.8m)(1.5m)(4.1m)(4.9m)(7.2m)(15.0m)(22.8m)

Accounts Payable

(1.5m)(701.0k)3.4m(570.0k)495.0k(780.0k)(709.0k)2.9m3.3m
USDFY, 2017

EV/EBIT

107.5 x

EV/CFO

86.3 x

Revenue/Employee

598.5k

Debt/Equity

0.2 x

Debt/Assets

0.1 x

Financial Leverage

1.3 x

P/E Ratio

50.4
Show all financial metrics

Repligen Operating Metrics

FY, 2017FY, 2018FY, 2019

Patent Applications

85 106

Patents Issued

44 52

Product Lines

3 4

Trademarks (Foreign)

34
Show all operating metrics

Repligen Acquisitions / Subsidiaries

Company NameDateDeal Size
C Technologies, Inc.
Repligen Europe B.V.
Repligen GmbH
Repligen India Private Limited
Repligen Japan LLC
Repligen Korea Co. Ltd.
Repligen (Shanghai) Biotechnology Co. Ltd.
Repligen Singapore Pte. Ltd.
Repligen Sweden AB
Spectrum Lifesciences, LLC

Repligen Revenue Breakdown

Embed Graph

Repligen revenue breakdown by business segment: 99.9% from Product Revenue and 0.1% from Other

Human Capital Metrics

Embed Graph
Show all human capital metrics

Repligen Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

Repligen Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Repligen Online and Social Media Presence

Embed Graph

Repligen News and Updates

Repligen Corporation Announces Closing of Public Offering of $312.2 Million, Including Full Exercise of Underwriters’ Option

WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1.725 million shares of its common stock at a public offering price of $181 per share for gross proceeds, be…

Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock

WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of 1.5 million shares of its common stock. In addition, Repligen Corporation expects to grant the underwriters a 30-day option to purchase up …

Repligen strengthens downstream offering with $200m ARTeSYN acquisition

Repligen says it has established itself as a premier player in single-use systems, integrated flow paths, and assemblies following a triumvirate of bolt-on acquisitions.

Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions

WALTHAM, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held ARTeSYN Biosolutions (“ARTeSYN”) for approximately…

Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines

WALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand …

Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance

WALTHAM, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2020. Provided in this press release are financial highlights for the three- and …
Show more

Repligen Frequently Asked Questions

  • When was Repligen founded?

    Repligen was founded in 1981.

  • Who are Repligen key executives?

    Repligen's key executives are Tony J. Hunt, Jon K. Snodgres and Ralf Kuriyel.

  • How many employees does Repligen have?

    Repligen has 761 employees.

  • What is Repligen revenue?

    Latest Repligen annual revenue is $270.2 m.

  • What is Repligen revenue per employee?

    Latest Repligen revenue per employee is $355.1 k.

  • Who are Repligen competitors?

    Competitors of Repligen include United Therapeutics, Luminex and SCIEX.

  • Where is Repligen headquarters?

    Repligen headquarters is located at 41 Seyon St #100, Waltham.

  • Where are Repligen offices?

    Repligen has offices in Waltham, Bridgewater Township, Clifton Park, Compton and in 10 other locations.

  • How many offices does Repligen have?

    Repligen has 14 offices.